H.C. Wainwright has elevated its price target for Instil Bio (TIL, Financial) from $105 to $125, maintaining a Buy rating. This decision comes after the company unveiled encouraging Phase 1/2 dose escalation results for AXN-2510 in treating first-line non-small cell lung cancer. The firm has also increased its estimated probability of approval for the treatment from 25% to 35%.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Instil Bio Inc (TIL, Financial) is $112.00 with a high estimate of $180.00 and a low estimate of $51.00. The average target implies an upside of 355.10% from the current price of $24.61. More detailed estimate data can be found on the Instil Bio Inc (TIL) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Instil Bio Inc's (TIL, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
